COMPLIANCE CERTIFICATE UNDER REGULATION 74(5) FOR THE QUARTER ENDED 31ST DECEMBER, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Limited has submitted a quarterly compliance certificate to BSE under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate was issued by Adroit Corporate Services Pvt. Ltd., the company's Registrar and Share Transfer Agent (RTA), on 2 January 2026. It confirms that all physical share certificates received for dematerialisation during the quarter ended 31 December 2025 were properly verified, accepted or rejected by the depository, mutilated and cancelled, and the company's register of members was updated with the depository's name as the registered owner within the stipulated 15-day timeline. No specific numbers on share volumes or rejections are disclosed in the filing.
This is a routine procedural compliance filing with no material impact on the company's financials or share price. It simply confirms that the RTA handled share dematerialisation requests properly during the October–December 2025 quarter, which is a standard regulatory requirement for all listed companies.